Clinical Trials

More than 20% of patients with cancer participate in some form of clinical study, and that number is considered a “floor” estimate, according to study results published in Journal of Clinical Oncology.

A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.

Pregnant and lactating women have historically been excluded from most clinical research, often due to perceptions of greater legal liability if a woman, her fetus or infant is harmed by an intervention.

DENVER — A phase 3 trial of ulixacaltamide for essential tremor will involve at-home patient participation and a clinical endpoint of activities of daily living, according to a speaker at the American Academy of Neurology annual meeting.

ATLANTA — In this Healio video exclusive, Pamela S. Douglas, MD, MACC, FASE, FAHA, discusses an American College of Cardiology initiative created to increase diversity and equity in clinical trials research leadership.

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

WEST PALM BEACH, Fla. — Inclusion of underrepresented racial and ethnic groups, along with older patients, patients from rural areas and uninsured patients in multiple sclerosis-targeted clinical trials is likely to improve outcomes, according to a speaker.